Mariam Taha

Dr. Mariam Taha

Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
DKDilini Kumaran
Dilini Kumaran
MTMariam Taha
Mariam Taha
QYQiLong Yi
QiLong Yi
SRSandra Ramirez-Arcos
Sandra Ramirez-Arcos
JDJean-Simon Diallo
Jean-Simon Diallo
HAHesham Abdelbary
Hesham Abdelbary
The inability to effectively treat biofilm-related infections is a major clinical challenge. This has been attributed to the heightened antibiotic tolerance conferred to bacterial cells embedded within biofilms. Lytic bacteriophages (phages) have evolved to effectively infect and eradicate biofilm-associated cells. The current study was designed to investigate the ability of phage treatment to enhance the activity of antibiotics against biofilm-forming Staphylococcus aureus. The biofilm positive S. aureus strain ATCC 35556, the lytic S. aureus phage SATA-8505, and five antibiotics (cefazolin, vancomycin, dicloxacillin, tetracycline, and linezolid), used to treat S. aureus infections, were tested in this study. The ability of the SATA-8505 phage to augment the effect of these antibiotics against biofilm-associated S. aureus cells was assessed by exposing them to one of the five following treatment strategies: (i) antibiotics alone, (ii) phage alone, (iii) a combination of the two treatments simultaneously, (iv) staggered exposure to the phage followed by antibiotics, and (v) staggered exposure to antibiotics followed by exposure to phage. The effect of each treatment strategy on biofilm cells was assessed by enumerating viable bacterial cells. The results demonstrate that the treatment of biofilms with either SATA-8505, antibiotics, or both simultaneously resulted in minimal reduction of viable biofilm-associated cells. However, a significant reduction [up to 3 log colony forming unit (CFU)/mL] was observed when the phage treatment preceded antibiotics. This effect was most pronounced with vancomycin and cefazolin which exhibited synergistic interactions with SATA-8505, particularly at lower antibiotic concentrations. This in vitro study provides proof of principle for the ability of phages to augment the activity of antibiotics against S. aureus biofilms. Our results also demonstrate that therapeutic outcomes can be influenced by the sequence in which these therapeutic agents are administered, and the nature of their interactions. Further investigation into the interactions between lytic phages and antibiotics against various biofilm-forming organisms is important to direct future clinical translation of efficacious antibiotic–phage combination therapeutic strategies.

22 November 2017 in Journal of Orthopaedic Research
Verified
Journal Article
Closed access
PDF file
ZAZarique Z. Akanda
Zarique Z. Akanda
MTMariam Taha
Mariam Taha
HAHesham Abdelbary
Hesham Abdelbary

20 June 2018 in Current Reviews in Musculoskeletal Medicine
Verified
Journal Article
Closed access
PDF file
MTMariam Taha
Mariam Taha
HAHesham Abdelbary
Hesham Abdelbary
FRF. Patrick Ross
F. Patrick Ross
ACAlberto V. Carli
Alberto V. Carli

16 February 2017 in Transfusion
Verified
Journal Article
Closed access
PDF file
MLMaria Loza‐Correa
Maria Loza‐Correa
YKYuntong Kou
Yuntong Kou
MTMariam Taha
Mariam Taha
MKMiloslav Kalab
Miloslav Kalab
JRJennifer Ronholm
Jennifer Ronholm
SRSandra Ramirez-Arcos
Sandra Ramirez-Arcos

29 May 2014 in Transfusion
Verified
Journal Article
Closed access
PDF file
MTMariam Taha
Mariam Taha
MKMiloslav Kalab
Miloslav Kalab
QYQi‐Long Yi
Qi‐Long Yi
CLCarey Landry
Carey Landry
VGValerie Greco‐Stewart
Valerie Greco‐Stewart
SRSandra Ramirez-Arcos
Sandra Ramirez-Arcos

25 January 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MLMaria Loza-Correa
Maria Loza-Correa
JUAN ALFONSO Ayala SerranoJUAN ALFONSO Ayala Serrano
JUAN ALFONSO Ayala Serrano
IPIris Perelman
Iris Perelman
KHKeith Hubbard
Keith Hubbard
MKMiloslav Kalab
Miloslav Kalab
SRSandra Ramirez-Arcos
Sandra Ramirez-Arcos
Staphylococcus epidermidis is a bacterium frequently isolated from contaminated platelet concentrates (PCs), a blood product used to treat bleeding disorders in transfusion patients. PCs offer an accidental niche for colonization of S. epidermidis by forming biofilms and thus avoiding clearance by immune factors present in this milieu. Using biochemical and microscopy techniques, we investigated the structural changes of the peptidoglycan (PG) and the biofilm matrix of S. epidermidis biofilms formed in whole-blood derived PCs compared to biofilms grown in glucose-supplemented trypticase soy broth (TSBg). Both, the PG and the biofilm matrix are primary mechanisms of defense against environmental stress. Here we show that in PCs, the S. epidermidis biofilm matrix is mainly of a proteinaceous nature with extracellular DNA, in contrast to the predominant polysaccharide nature of the biofilm matrix formed in TSBg cultures. PG profile studies demonstrated that the PG of biofilm cells remodels during PC storage displaying fewer muropeptides variants than those observed in TSBg. The PG muropeptides contain two chemical modifications (amidation and O-acetylation) previously associated with resistance to antimicrobial agents by other staphylococci. Our study highlights two key structural features of S. epidermidis that are remodeled when exposed to human platelets and could be used as targets to reduce septic transfusions events.